Health Technology

Santen Pharmaceutical Co., Ltd.

In the news

Japan's midsize drugmakers find niche in richer Southeast Asians Aug 25, 2019
Japanese drugmaker Santen forays into India Aug 8, 2019
Premium eyedrops sales boom with so many people staring at screens Mar 20, 2018
Tourists to Japan now spending more on the cheap Aug 29, 2017
Japan's Santen sets sights on world with 15-minute glaucoma treatment Mar 18, 2017

See more articles on Santen Pharmaceutical Co., Ltd.

Business Summary

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	266,257M	2,369.41M
Gross Profit	146,852M	1,306.83M
Operating income	35,976M	320.14M
Income before tax	37,220M	331.21M
Net income	27,224M	242.26M
EBITDA	53,031M	471.92M
Diluted EPS	67.96	0.60
Dividends Per Share	32	0.28
Total Assets	459,976M	3,789.70M
Total liabilities	123,134M	1,014.49M
Total equity	337,488M	2,780.53M
Operating cash flow	46,043M	409.73M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	224,942M	234,026M	241,555M	249,605M	266,257M
Gross Profit	129,618M	134,165M	134,703M	140,734M	146,852M
Operating income	38,637M	41,242M	40,125M	37,068M	35,976M
Income before tax	39,261M	43,117M	32,091M	12,046M	37,220M
Net income	35,247M	31,953M	23,616M	9,315M	27,224M
EBITDA	49,533M	52,211M	56,698M	54,990M	53,031M
Diluted EPS	86.42	78.43	59.00	23.25	67.96
Dividends Per Share	26	26	27	28	32
Total Assets	388,463M	391,186M	408,768M	405,285M	459,976M
Total liabilities	100,904M	98,614M	106,208M	95,641M	123,134M
Total equity	285,823M	290,900M	302,865M	310,181M	337,488M
Operating cash flow	42,843M	32,894M	39,947M	38,808M	46,043M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	2,029.56M	2,110.34M	2,221.69M	2,353.48M	2,369.41M
Gross Profit	1,169.49M	1,209.84M	1,238.92M	1,326.96M	1,306.83M
Operating income	348.60M	371.90M	369.04M	349.50M	320.14M
Income before tax	354.23M	388.81M	295.15M	113.57M	331.21M
Net income	318.02M	288.13M	217.20M	87.82M	242.26M
EBITDA	446.91M	470.81M	521.47M	518.49M	471.92M
Diluted EPS	0.77	0.70	0.54	0.21	0.60
Dividends Per Share	0.23	0.23	0.24	0.26	0.28
Total Assets	3,652.68M	3,534.22M	3,786.46M	3,667.73M	3,789.70M
Total liabilities	948.79M	890.94M	983.81M	865.52M	1,014.49M
Total equity	2,687.56M	2,628.17M	2,805.47M	2,807.06M	2,780.53M
Operating cash flow	386.55M	296.62M	367.41M	365.91M	409.73M

Valuation Measures

Mar 2022
PER	18.02
ROA	6.29%
ROE	8.40%
Operating margin	13.51%
Profit margin	10.22%

Key executives

President & Chief Executive Officer: Takeshi Ito
CFO, General Manager-Finance & Administration: Kazuo Koshiji
Chief Information Officer, GM-Digital & IT: Minori Hara
Chief Compliance Officer & Executive Officer: Mika Masunari
Executive Officer: Kenji Morishima

Shareholders

Black Creek Investment Management, Inc. (5.3%)
Nomura Asset Management Co., Ltd. (5.1%)
Massachusetts Financial Services Co. (4.3%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.6%)
Mitsubishi UFJ Financial Group, Inc. (3.6%)
MFS International (UK) Ltd. (2.9%)
Nikko Asset Management Co., Ltd. (2.8%)
Nippon Life Insurance Co. (2.7%)
The Vanguard Group, Inc. (2.3%)
SPARX Asset Management Co., Ltd. (2.0%)

Contact Details

Website:http://www.santen.co.jp
Address: Grand Front Osaka Tower A, 25/F, 4-20 Ofuka-cho, Osaka, 530-8552, Japan
Phone: +81.6.7664.8621

Related Companies

Chongqing Santen Kerui Pharmaceutical Co. Ltd.
Santen China Investment Co. Ltd.
Santen LLC
Santen Pharmaceutical Performance Share Unit
Santen Pharmaceutical (Hong Kong) Ltd.
Phacor, Inc.
Santen Canada, Inc.
Santen Pharmaceutical Restricted Stock Compensation Plan
Santen Philippines, Inc.
Santen Pharma Malaysia Sdn. Bhd.
Santen (Thailand) Co. Ltd.
Santen SA
Santen Eye Care Co., Ltd.
Santen Business Services Co. Ltd.
Claire Co. Ltd.
Santen Pharmaceutical Spain SL
SantenPharma AB
Santen India Pvt Ltd.
Santen Pharmaceutical Korea Co. Ltd.
Santen Pharmaceutical Asia Pte Ltd.
Santen Pharmaceutical Sales & Marketing (Suzhou) Co., Ltd.
Taiwan Santen Pharmaceutical Co. Ltd.
Santen SAS
Santen Pharmaceutical Trust
Santen Pharmaceutical (China) Co. Ltd.
Santen Holdings U.S., Inc.
Santen Pharmaceutical Pension Fund
Santen GmbH
Santen Oy
Santen Holdings EU BV

Competitors

Nicox SA
EyePoint Pharmaceuticals, Inc.
HLB Therapeutics Co., Ltd.
CHO Pharma, Inc.
Satellos Bioscience Inc
PharmaEssentia Corp.

Last Updated on 27 Jan, 2023